Feature | Cath Lab | November 06, 2017

ORBITA Study Finds No Improvement in Exercise Time Over Placebo in PCI Patients

Results from the ORBITA Trial Reported at TCT 2017 and Published Simultaneously in The Lancet 

Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017

November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found no significant difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. Both groups were treated with medical therapy. 

Findings were reported at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The study was also published simultaneously in The Lancet. 

“In patients with medically treated angina and anatomically and hemodynamically severe single vessel coronary stenosis, PCI did not increase exercise time more than placebo,” said Rasha Al-Lamee, M.D., from Imperial College London. “Despite PCI markedly improving hemodynamic and imaging indices, there was no significant difference between PCI and placebo in exercise time increment. This first placebo-controlled trial of PCI for stable angina suggests that the common clinical observation of symptomatic improvement from PCI may well contain a placebo component.” 

Two hundred patients were randomized to receive either PCI or a placebo procedure between January 2014 and August 2017 at five sites within the United Kingdom. All patients were clinically eligible for PCI based on symptoms and at least one angiographically significant lesion ≥70% in a single vessel that was clinically appropriate for PCI. Patients with multi-vessel disease were excluded. The primary endpoint was change in exercise time on a treadmill. The trial was designed to detect an effect size difference of 30 seconds between the two study arms at six weeks. 

After enrollment, patients entered a six-week medical optimization phase, which included the introduction and intensive up-titration of anti-anginal medications. This was followed by a pre-randomization assessment that included symptom burden with Canadian Cardiovascular Society Class and the Seattle Angina questionnaire, functional capacity using cardiopulmonary exercise testing, myocardial ischemic burden using dobutamine stress echocardiography, and quality of life assessment using an EQ-5D-5L questionnaire.

Patients then underwent the blinded invasive procedure. The operator performing coronary angiography also performed blinded fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) measurements pre- and post-procedure. Patients had auditory isolation and, after the physiological measurements, received sedation. They were then randomized 1:1 to PCI with drug-eluting stents or a placebo procedure. PCI operators were blinded to all research test data using only non-research clinical information. In the placebo arm, patients were kept sedated for at least 15 minutes and the coronary catheters were withdrawn with no intervention performed. After a follow-up period of six weeks, patients completed the same tests as they did during the pre-randomization assessment.

Complete pre-randomization and follow-up data for exercise time was available in 104 patients in the PCI arm and 90 patients in the placebo arm. For the primary endpoint, there was no significant difference in mean exercise times at six weeks between the two groups (PCI minus placebo, 16.6 seconds, 95% CI -8.9 to 42.0, P=0.200). In pairwise assessments, exercise time increased from baseline in the PCI group (mean increase of 28.4 seconds (95% CI 11.6 to 45.1) but not in the placebo group (mean increase of 11.8 seconds (95% CI -7.8 to 31.3). There were no significant differences between study arms in other secondary endpoints of health-related quality of life measures including anginal symptom scores or quality of life, although improvements were noted in both arms. PCI was associated with a reduction in ischemia assessed by dobutamine stress echocardiography (change in wall motion stress index of -0.08 (95% CI -0.11 to -0.04) compared with +0.02 (95% CI -0.03 to 0.06), P=0.0011).

The ORBITA trial was funded by grants from the NIHR Imperial Biomedical Research Centre, Foundation for Circulatory Health, and Imperial College Healthcare Charity. Pressure wires were supplied by Philips Volcano. Al-Lamee reported receipt of speaker’s honoraria from Philips Volcano. 

For more information: www.crf.org

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 

Reference: 

1. Rasha Al-Lamee, David Thompson, Hakim-Moulay Dehbi,  et al. "Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.” Lancet. http://dx.doi.org/10.1016/S0140-6736(17)32714-9

 

Related Content

Now cleared by the FDA, PocketECG CRS is a new mobile cardiac rehabilitation system designed to provide high-quality ECG monitoring and automated arrhythmia detection during rehabilitation training. The device monitors a patient's heart rhythm and heart rate to safely guide the intensity and duration of rehabilitation exercises in real-time.

Now cleared by the FDA, PocketECG CRS is a new mobile cardiac rehabilitation system designed to provide high-quality ECG monitoring and automated arrhythmia detection during rehabilitation training. The device monitors a patient's heart rhythm and heart rate to safely guide the intensity and duration of rehabilitation exercises in real-time.

Technology | Cardiac Rehabilitation | July 24, 2018
July 23, 2018 — The U.S.
cardiac rehabilitation, depression, death risk, heart surgery, Intermountain Medical Center Heart Institute, AHA Scientific Sessions 2016
News | Cardiac Rehabilitation | November 15, 2016
Depression has been known to be associated with poor cardiovascular outcomes. But if patients who are depressed attend...
cardiac rehab, cardiac rehabilitation, CHF, heart failure

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. Patient engagement is key to improving CHF patient quality of life and outcomes without the use of drugs and devices.

Feature | Cardiac Rehabilitation | May 24, 2016 | Karen D. Walker, RN, MSN, and Stephanie Rejc, MS
Cardiac rehabilitation and exercise training has been shown to improve clinical status and outcomes in congestive hea
cardiac rehab, digital health tools, weight loss, ACC study, Mayo Clinic
News | Cardiac Rehabilitation | March 31, 2016
New research finds that adding a digital health tool to traditional cardiac rehabilitation appears to help people...
cardiac rehab after angioplasty, rehabilitation, ACC, Randal J. Thomas, referral
Feature | Cardiac Rehabilitation | July 17, 2015
Hospitals in the Midwest were more likely than others to refer patients for guideline-recommended cardiac...
Overlay Init